There are no recommendations for routine monitoring.

- A pregnancy test is necessary if the patient misses a menstrual cycle.

- Patients taking warfarin should have an INR check one week following single-dose aprepitant administration due to aprepitant causing increased warfarin plasma concentrations via CYP34A inhibition.

- Monitor the quality of life and clinical response to the aprepitant using a modified functional living index-emesis (FLIE) or functional living index-emesis (FLIE) score.